share_log

Chemomab Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Israel BioFund GP Limited Partnership(9.99%),OrbiMed Israel GP Ltd.(9.99%), etc.

Chemomab Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-OrbiMed Israel BioFund GP Limited Partnership(9.99%),OrbiMed Israel GP Ltd.(9.99%)等

美股SEC公告 ·  2024/09/17 04:37
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息